PEPFAR, the President’s Emergency Plan for AIDS Relief, is the largest commitment any single nation has ever made to fight a single disease. Launched in 2003, the U.S.-funded program supports HIV prevention, treatment, and care in 55 countries and has saved more than 26 million lives since its creation. It operates across sub-Saharan Africa, the Caribbean, Asia, and parts of Eastern Europe and Latin America, making it one of the most far-reaching global health initiatives in history.
How PEPFAR Started
On May 27, 2003, the United States Leadership Against Global HIV/AIDS, Tuberculosis, and Malaria Act was signed into law, creating PEPFAR. At the time, the HIV/AIDS crisis was devastating sub-Saharan Africa. Antiretroviral drugs existed but were largely inaccessible in the hardest-hit countries, and millions of people were dying from a disease that had become treatable in wealthier nations. PEPFAR was designed as an emergency response to close that gap, channeling billions of dollars into building the infrastructure needed to get medication, testing, and prevention services to the people who needed them most.
The program has been reauthorized by Congress multiple times since then, with bipartisan support. The PEPFAR Extension Act of 2024 proposed extending the program’s authorization through 2030. The Biden Administration requested at least $4.7 billion annually for PEPFAR in its budget proposals to Congress.
Where PEPFAR Operates
PEPFAR runs full country programs in 25 nations, most of them in Africa: Angola, Botswana, Burundi, Cameroon, Côte d’Ivoire, the Democratic Republic of Congo, Eswatini, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Nigeria, Rwanda, South Africa, South Sudan, Tanzania, Uganda, Zambia, and Zimbabwe. Outside Africa, country programs operate in the Dominican Republic, Haiti, Ukraine, and Vietnam.
Beyond those, PEPFAR supports regional programs covering parts of Asia (including India, Cambodia, Indonesia, and Thailand), West Africa (including Ghana, Burkina Faso, and Senegal), and the Western Hemisphere (including Brazil, Guyana, Jamaica, and several Central American countries). In total, the program reaches 55 countries, though the scale of investment varies widely depending on a country’s epidemic burden.
What the Program Actually Does
PEPFAR’s core work falls into three categories: treating people who are already living with HIV, preventing new infections, and strengthening the health systems that make both possible.
On the treatment side, PEPFAR funds antiretroviral therapy, the daily medication that suppresses HIV to undetectable levels and allows people to live normal lifespans. The program supports testing and diagnosis so people learn their status, then connects them to clinics where they can start and stay on treatment. This is the single biggest driver behind the 26 million lives saved figure: before PEPFAR, getting these drugs to rural clinics in low-income countries was nearly impossible.
Prevention efforts are equally aggressive. In the first quarter of fiscal year 2024 alone, PEPFAR supported voluntary medical male circumcision for over 762,000 men and boys, a procedure that reduces a man’s risk of acquiring HIV through heterosexual contact by roughly 60%. During that same period, nearly 530,000 people were newly enrolled on PrEP, a daily pill that prevents HIV infection in people who don’t have the virus but are at high risk. PEPFAR also funds programs to prevent mother-to-child transmission during pregnancy and childbirth, which has resulted in millions of babies being born HIV-free in countries where vertical transmission was once common.
Building Health Systems, Not Just Fighting HIV
One of the less visible but most consequential parts of PEPFAR is its investment in health infrastructure. Over a single recent year, the program invested nearly $1.2 billion to support more than 325,000 health workers across 29 partner countries in Africa. These are doctors, nurses, community health workers, and epidemiologists who deliver HIV services but also serve their communities in broader ways.
PEPFAR has funded laboratory networks, supply chains for medications, electronic health record systems, and disease surveillance tools. These investments don’t disappear when the HIV crisis improves. Countries that built diagnostic labs for HIV testing used that same infrastructure during COVID-19 and Ebola outbreaks. The program’s architects have always framed this as a dual purpose: control the HIV epidemic now while leaving behind health systems strong enough to handle future crises.
The Scale of Impact
According to UNAIDS, PEPFAR saved more than 26 million lives and averted nearly 5 million new HIV infections between 2003 and 2024. To put that in perspective, 26 million is roughly the population of Australia. Before PEPFAR, many of the countries it now serves had life expectancies that had dropped by a decade or more because of AIDS-related deaths. In several southern African nations, life expectancy has rebounded dramatically since treatment became widely available.
The program’s influence extends beyond the numbers. PEPFAR fundamentally changed the global conversation about what was possible in public health. It demonstrated that delivering complex medical treatment at scale in resource-limited settings could work, challenging the assumption that antiretroviral therapy was too complicated or expensive for low-income countries. That proof of concept has shaped how the global health community approaches other diseases since.
Why PEPFAR Remains Contentious
Despite its bipartisan origins, PEPFAR has periodically become a subject of political debate. Reauthorization discussions have sometimes stalled over questions about how funds are used, particularly around reproductive health services. The program’s annual budget of roughly $4.7 billion also draws scrutiny from lawmakers who question the scale of foreign aid spending, even as public health organizations argue the investment pays for itself through reduced disease burden and improved stability in partner countries.
Disruptions to PEPFAR funding have immediate, real-world consequences. Because millions of people depend on PEPFAR-supported clinics for their antiretroviral medication, any interruption in supply risks treatment gaps. When a person living with HIV stops taking their medication, the virus can rebound, their health deteriorates, and drug-resistant strains can develop. For this reason, global health organizations closely monitor the program’s legislative status and funding levels, treating continuity as a life-or-death issue for the populations it serves.